Gray-market retatrutide sends gym user to hospital, clinician tells The Scientist
Clinician Karthik Achari says phase 2 trial data for Eli Lilly's unapproved triple agonist was repurposed as influencer marketing, fuelling knock-off supply.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 25 00:16 ETSource: the-scientist.com
The wire
- 01A man injected 50 units of retatrutide on a bodybuilder's advice and was hospitalised when his gut stopped moving, said clinician Karthik Achari, who founded standards body PepMD.
- 02Retatrutide, a GLP-1/GIP/glucagon polypeptide, is still in clinical development and approved by no regulator, yet unapproved copies circulate widely among consumers.
- 03An FDA advisory panel recently weighed whether compounders should be allowed to make such peptides; the account here is a single clinician's report, not systematic adverse-event data.
From the source
Read at the-scientist.comUnregulated Peptides Have Flooded the Market. Will Regulators Respond?
D etermined to optimize his physique, a dedicated gym-goer was intrigued when a bodybuilder friend suggested he try a substance called retatrutide. If he injected 50 units of the peptide, he would start losing weight, the bodybuilder said. After doing so, the man ended up in the hospital due to one of the nasty side effects of this category of weight-loss drugs. “His gut basically stopped moving,”
